Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M 

June 16, 2022  |  Startland News Staff

Dr. F. Nicholas Franano, Artio Medical; photo courtesy of Max McBride

Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.

Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.

Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.

Click here to read more about Artio’s $12 million funding infusion in 2021. 

“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.

“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.” 

Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.

Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.

Click here to learn more about Artio’s portfolio of products.

startland-tip-jar

TIP JAR

Did you enjoy this post? Show your support by becoming a member or buying us a coffee.

Tagged , , ,
Featured Business
    Featured Founder

      2022 Startups to Watch

        stats here

        Related Posts on Startland News

        This meal is metal: Elephant Wings rocks concert of flavors with chef’s Indian fusion setlist

        By Tommy Felts | January 25, 2024

        Ameet Malhotra’s just-released cover of Indian fusion is fuel to the fire of that which diners’ desire, the chef and owner of Elephant Wings said. Newly opened this month at Parlor KC in the Crossroads, two of the restaurant’s popular menu items include Malhotra’s tikka masala poutine and the Bombay-mi — his version of the…

        NXTSTAGE taps trio of KC entrepreneurs to help their companies grow revenue, scale

        By Tommy Felts | January 25, 2024

        WICHITA — Three Kansas City startup founders are among 20 early-stage companies selected for the latest NXTUS program aimed at boosting innovation from within urban and rural areas throughout the state of Kansas. Joining the 2024 NXTSTAGE Customer Traction Cohort: Joy Broils, Hustle & Ground, Shawnee; Mark Lukenbill, Mpruv Sports, Basehor; and Crystal Webster, Sharing…

        Study with USDA researchers affirms startup’s AI-powered facial recognition for cows can detect sick animals

        By Tommy Felts | January 25, 2024

        A collaborative study between an Overland Park animal agtech startup and the U.S. Department of Agriculture successfully corroborated MyAnIML’s predictive ability to proactively manage devastating disease outbreaks in cattle production, the company announced this week. MyAnIML uses first-of-its-kind, proprietary facial recognition and deep learning technology to analyze cow muzzles — accurately predicting Infectious Bovine Keratoconjunctivitis…

        Tammie Wahaus, ELIAS Animal Health

        KC startup’s bone cancer treatment for dogs earns ‘milestone’ USDA validation

        By Tommy Felts | January 25, 2024

        A decade of hard work by a veteran entrepreneur and her Olathe-based team has cleared a significant hurdle on the pathway to licensure as its first-in-class adoptive cell therapy for dog cancer gains a critical nod of approval from federal regulators. ELIAS Animal Health, a leading companion animal cancer therapeutics company, recently announced that the…